81.16

0.86% 0.69

Handel nachbörslich: 81.16

Edwards Lifesciences Corp (EW)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt EW? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$80.47

Offen:

$80.92

24-Stunden-Volumen:

5.83M

Relative Volume:

1.34

Marktkapitalisierung:

$47.61B

Einnahmen:

$5.69B

Nettoeinkommen (Verlust:

$4.15B

KGV:

11.68

EPS:

6.95

Netto-Cashflow:

$623.10M

1W Leistung:

+5.53%

1M Leistung:

+3.77%

6M Leistung:

+10.84%

1J Leistung:

+27.53%

1-Tages-Spanne:

$80.45

$81.88

1-Wochen-Bereich:

$75.39

$83.00

52-Wochen-Spanne:

$59.41

$83.00

Edwards Lifesciences Corp Stock (EW) Company Profile

Firmenname

Edwards Lifesciences Corp

Sektor

Healthcare (1166)

Branche

Medical Devices (150)

Telefon

(949) 250-2500

Adresse

ONE EDWARDS WAY, IRVINE, CA

Mitarbeiter

15,800

Twitter

@edwardslifesci

Nächster Verdiensttermin

2025-02-11

Neueste SEC-Einreichungen

EW's Discussions on Twitter

Vergleichen Sie EW mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
EW Edwards Lifesciences Corp	81.16	46.04B	5.69B	4.15B	623.10M	6.95
ABT Abbott Laboratories	128.55	219.83B	43.11B	13.98B	6.66B	7.98
BSX Boston Scientific Corp	106.76	156.58B	18.49B	2.51B	2.72B	1.68
SYK Stryker Corp	400.41	153.13B	23.22B	2.86B	3.58B	7.40
MDT Medtronic Plc	91.64	117.84B	33.54B	4.66B	5.19B	3.62

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-04-24	Hochstufung	Piper Sandler	Neutral → Overweight
2025-01-30	Hochstufung	Stifel	Hold → Buy
2025-01-16	Herabstufung	Wolfe Research	Peer Perform → Underperform
2024-12-16	Hochstufung	BofA Securities	Neutral → Buy
2024-10-11	Fortgesetzt	Morgan Stanley	Equal-Weight
2024-09-18	Herabstufung	Jefferies	Buy → Hold
2024-07-31	Hochstufung	Daiwa Securities	Neutral → Outperform
2024-07-29	Hochstufung	Wolfe Research	Underperform → Peer Perform
2024-07-25	Herabstufung	BofA Securities	Buy → Neutral
2024-07-25	Herabstufung	JP Morgan	Overweight → Neutral
2024-07-25	Herabstufung	Robert W. Baird	Outperform → Neutral
2024-07-25	Herabstufung	TD Cowen	Buy → Hold
2024-07-25	Herabstufung	Truist	Buy → Hold
2024-05-30	Eingeleitet	Goldman	Buy
2024-05-22	Hochstufung	Citigroup	Neutral → Buy
2024-05-14	Hochstufung	Deutsche Bank	Hold → Buy
2024-03-07	Hochstufung	BofA Securities	Neutral → Buy
2024-02-02	Hochstufung	Wells Fargo	Equal Weight → Overweight
2024-01-04	Herabstufung	Evercore ISI	Outperform → In-line
2023-12-11	Herabstufung	Citigroup	Buy → Neutral
2023-11-28	Herabstufung	Wolfe Research	Peer Perform → Underperform
2023-09-26	Hochstufung	Oppenheimer	Perform → Outperform
2023-07-19	Eingeleitet	Robert W. Baird	Outperform
2023-05-30	Fortgesetzt	Morgan Stanley	Overweight
2023-03-29	Eingeleitet	UBS	Neutral
2023-03-08	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-02-06	Herabstufung	Raymond James	Outperform → Mkt Perform
2023-01-31	Herabstufung	Bernstein	Outperform → Underperform
2023-01-30	Herabstufung	Piper Sandler	Overweight → Neutral
2022-12-06	Herabstufung	Stifel	Buy → Hold
2022-10-28	Herabstufung	Oppenheimer	Outperform → Perform
2022-10-26	Eingeleitet	Mizuho	Buy
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Buy
2022-07-29	Herabstufung	Canaccord Genuity	Buy → Hold
2022-04-13	Eingeleitet	Truist	Buy
2022-04-06	Eingeleitet	Wolfe Research	Outperform
2022-03-16	Hochstufung	Bernstein	Mkt Perform → Outperform
2022-03-02	Fortgesetzt	BofA Securities	Neutral
2022-02-02	Hochstufung	UBS	Neutral → Buy
2022-01-27	Bestätigt	Citigroup	Buy
2022-01-27	Bestätigt	Evercore ISI	Outperform
2022-01-27	Bestätigt	Raymond James	Outperform
2022-01-27	Bestätigt	Stifel	Buy
2022-01-27	Bestätigt	UBS	Neutral
2021-12-17	Hochstufung	JP Morgan	Neutral → Overweight
2021-12-15	Hochstufung	Citigroup	Neutral → Buy
2021-12-10	Eingeleitet	RBC Capital Mkts	Outperform
2021-12-06	Hochstufung	Wells Fargo	Equal Weight → Overweight
2021-07-30	Bestätigt	Canaccord Genuity	Buy
2021-07-30	Bestätigt	Deutsche Bank	Hold
2021-07-30	Bestätigt	Jefferies	Buy
2021-07-30	Bestätigt	Morgan Stanley	Overweight
2021-07-30	Bestätigt	Oppenheimer	Outperform
2021-07-30	Bestätigt	Stifel	Buy
2021-07-30	Bestätigt	UBS	Neutral
2021-07-30	Bestätigt	Wells Fargo	Equal Weight
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-15	Eingeleitet	Atlantic Equities	Neutral
2021-04-05	Hochstufung	Evercore ISI	In-line → Outperform
2020-12-16	Herabstufung	Citigroup	Buy → Neutral
2020-12-11	Bestätigt	Canaccord Genuity	Buy
2020-09-11	Eingeleitet	Wolfe Research	Underperform
2020-04-28	Herabstufung	Wells Fargo	Overweight → Equal Weight
2020-04-17	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-13	Eingeleitet	Goldman	Neutral
2020-02-06	Fortgesetzt	BTIG Research	Neutral
2020-01-10	Eingeleitet	Oppenheimer	Outperform
2020-01-02	Herabstufung	Evercore ISI	Outperform → In-line
2019-10-24	Bestätigt	Canaccord Genuity	Buy
2019-09-23	Eingeleitet	Piper Jaffray	Overweight
2019-07-24	Bestätigt	BofA/Merrill	Buy
2019-03-18	Bestätigt	Canaccord Genuity	Buy
2019-01-18	Hochstufung	BofA/Merrill	Neutral → Buy
2019-01-03	Eingeleitet	Deutsche Bank	Hold
2018-11-28	Eingeleitet	UBS	Neutral
2018-10-16	Eingeleitet	Barclays	Underweight
2018-10-02	Herabstufung	BofA/Merrill	Buy → Neutral
2018-10-02	Herabstufung	Guggenheim	Buy → Neutral

Alle ansehen

Edwards Lifesciences Corp Aktie (EW) Neueste Nachrichten

12:21 PM

Edwards Lifesciences’ SAPIEN 3 Study: A Market Game-Changer? - TipRanks

12:21 PM

Jul 29, 2025

Edwards Lifesciences Stock (EW) Opinions on Q2 Earnings Beat - Quiver Quantitative

Jul 29, 2025

Edwards Lifesciences’ Pivotal Trial: A Game-Changer for Tricuspid Valve Repair? - TipRanks

Jul 29, 2025

A Quick Look at Today's Ratings for Edwards Lifesciences(EW.US), With a Forecast Between $84 to $100 - 富途牛牛

Jul 29, 2025

Edwards Lifesciences Corporation (NYSE:EW) Q2 2025 Earnings Call Transcript - Insider Monkey

Jul 29, 2025

Analysts upgrade Edwards as TAVR segment improves - MassDevice

Jul 29, 2025

BTIG upgrades Edwards Lifesciences stock to Buy on TAVR segment stability - Investing.com

Jul 29, 2025

Edwards Lifesciences prevails in heart valve dispute at the UPC - JUVE Patent

Jul 29, 2025

How Edwards Lifesciences Corporation stock reacts to Fed policy changesCommunity Verified Stock Suggestions Drive Volume - metal.it

Jul 29, 2025

Jul 28, 2025

Edwards Lifesciences Insider Makes a Major Stock Move! - TipRanks

Jul 28, 2025

Edwards Lifesciences Reports Strong Growth and Raises Guidance - TipRanks

Jul 28, 2025

Edwards Lifesciences debuts heart valve failure PSA as Rams training camp begins - Medical Marketing and Media

Jul 28, 2025

Edwards Lifesciences stock price target raised to $85 by Bernstein - Investing.com

Jul 28, 2025

Edwards Lifesciences stock price target raised to $85 by UBS on strong TAVR sales - Investing.com

Jul 28, 2025

Edwards Lifesciences’ SWOT analysis: strong TAVR growth boosts stock outlook - Investing.com

Jul 28, 2025

Jul 27, 2025

When is Edwards Lifesciences Corporation stock expected to show significant growthExceptional return forecasts - jammulinksnews.com

Jul 27, 2025

Is Edwards Lifesciences Corporation a growth stock or a value stockDiscover breakthrough stocks before the crowd - jammulinksnews.com

Jul 27, 2025

How volatile is Edwards Lifesciences Corporation stock compared to the marketFree Stock Selection - jammulinksnews.com

Jul 27, 2025

Edwards Lifesciences (EW) Announces Executive Leadership Change - GuruFocus

Jul 27, 2025

Can Edwards Lifesciences Corporation stock recover from recent declineTriple Return With Stability - metal.it

Jul 27, 2025

Edwards Lifesciences stock price target raised to $90 by Piper Sandler - Investing.com

Jul 27, 2025

Jul 26, 2025

Earnings Preview: What To Expect From Edwards Lifesciences' Report - MSN

Jul 26, 2025

Edwards Lifesciences Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo.co

Jul 26, 2025

Edwards Lifesciences stock price target raised to $84 from $75 at TD Cowen - Investing.com

Jul 26, 2025

Edwards Lifesciences stock price target raised to $89 at RBC on growth outlook - Investing.com

Jul 26, 2025

Jul 25, 2025

JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Followin - GuruFocus

Jul 25, 2025

Edwards Lifesciences (EW) Target Price Raised by JP Morgan | EW Stock News - GuruFocus

Jul 25, 2025

Edwards Lifesciences sales up nearly 12% in Q2 - MassDevice

Jul 25, 2025

Edwards Lifesciences Corp. stock outperforms competitors on strong trading day - MarketWatch

Jul 25, 2025

Edwards Lifesciences Corporation Stock Analysis and ForecastPhenomenal returns - PrintWeekIndia

Jul 25, 2025

Edwards Lifesciences Q2 EarningsEdwards Lifesciences (NYSE:EW) - Benzinga

Jul 25, 2025

Edwards Exec Larry Wood Departs for Procept BioRobotics - Orange County Business Journal

Jul 25, 2025

Edwards Lifesciences (EW) Target Price Raised by Baird Analyst | - GuruFocus

Jul 25, 2025

Edwards Lifesciences’ MITRIS Valve Study: A Key Development for Investors - TipRanks

Jul 25, 2025

Edwards Lifesciences stock reaches 52-week high at 81.86 USD - Investing.com

Jul 25, 2025

Edwards Lifesciences Analysts Increase Their Forecasts After Stronger-Than-Expected Q2 Results - Benzinga

Jul 25, 2025

Edwards Lifesciences (EW) Surpasses Earnings and Revenue Expecta - GuruFocus

Jul 25, 2025

Edwards Lifesciences Q2 2025 Earnings Report - MarketBeat

Jul 25, 2025

Edwards Lifesciences (EW) Receives Price Target Upgrade from Deutsche Bank | EW Stock News - GuruFocus

Jul 25, 2025

Calculating The Intrinsic Value Of Edwards Lifesciences Corporation (NYSE:EW) - Yahoo Finance

Jul 25, 2025

Edwards Lifesciences (EW) Receives Price Target Boost from Baird | EW Stock News - GuruFocus

Jul 25, 2025

JPMorgan Adjusts Edwards Lifesciences (EW) Price Target Following Strong Q2 Results | EW Stock News - GuruFocus

Jul 25, 2025

Edwards loses longtime TAVR leader Larry Wood - Yahoo Finance

Jul 25, 2025